<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04722094</url>
  </required_header>
  <id_info>
    <org_study_id>PSO001</org_study_id>
    <nct_id>NCT04722094</nct_id>
  </id_info>
  <brief_title>Prevalence of Periodontitis in Patients With Plaque Psoriasis. A Cross-sectional Study</brief_title>
  <official_title>Prevalence of Periodontitis in Patients With Plaque Psoriasis. A Cross-sectional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Siena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Siena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Psoriasis is a chronic inflammatory disease with a multi-factorial etiology which affects the&#xD;
      epidermis and dermis. It affects around 1-3% of the general population and its most frequent&#xD;
      form is plaque psoriasis (around 80-90% of the overall psoriasis cases). Psoriasis severity&#xD;
      and extension are usually measured through 2 scores: Psoriasis Area Severity Index (PASI) and&#xD;
      Body Surface Area (BSA). Periodontitis is a chronic inflammatory disease mediated by the&#xD;
      biofilm and with a multi-factorial etiology. Its manifestation entails the destruction of the&#xD;
      periodontal tissues surrounding the teeth; the final stage of disease is characterised by&#xD;
      tooth loss. Periodontitis severity and extension are usually evaluated through surrogate&#xD;
      variables such as: BoP (Bleeding on Probing), PPD (Probing Pocket Depth) e REC (Recession).&#xD;
      Both diseases present overlapping genetic and pathophysiologic features, as well as common&#xD;
      risk factors (e.g. genetic polymorphisms, smoking habit, obesity, diabetes etc.).&#xD;
&#xD;
      miRNAs are small non-coding molecules involved in the regulation of various biologic&#xD;
      processes thanks to their interaction with mRNAs. Active inflammatory processes either in the&#xD;
      oral cavity or at a systemic level tend to alter the concentration of salivary miRNAs. No&#xD;
      study so far has ever profiled the levels of specific salivary miRNAs in patients with&#xD;
      psoriasis and periodontitis.&#xD;
&#xD;
      Some case-control studies highlighted a higher prevalence of periodontitis in patients with&#xD;
      psoriasis when compared to healthy controls. Nonetheless, epidemiological data regarding&#xD;
      periodontitis prevalence in patients with psoriasis are lacking; moreover, few data are&#xD;
      available regarding the relationship between the severity of psoriasis and the severity of&#xD;
      periodontitis, together with the effect of common risk factors (e.g. diet, obesity, physical&#xD;
      activity, sleep quality etc.).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">August 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 25, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Periodontitis in patients with Plaque psoriasis</measure>
    <time_frame>Baseline</time_frame>
    <description>The prevalence of patients with a diagnosis of periodontitis among the included cohort will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>relationship between salivary miRNAs concentration and the severity of psoriasis and periodontitis</measure>
    <time_frame>Baseline</time_frame>
    <description>salivary levels of miRNAs will be related to the severity of psoriasis and periodontitis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">147</enrollment>
  <condition>Psoriasis</condition>
  <condition>Plaque Psoriasis</condition>
  <condition>Periodontal Diseases</condition>
  <condition>Periodontitis</condition>
  <arm_group>
    <arm_group_label>Patients with Psoriasis</arm_group_label>
    <description>All patients pertaining to the Unit of Dermatology and affected by psoriasis will be screened for the inclusion in the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Full periodontal chart</intervention_name>
    <description>A full periodontal chart will be carried out including all biometric periodontal variables: Probing Pocket Depth (PPD), Bleeding on Probing (BoP), presence of Plaque, recession (REC), Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS), presence of furcation and mobility. Periodontal status, as assessed by the periodontal chart, will be evaluated following the New Classification of Periodontal and Peri implant diseases.</description>
    <arm_group_label>Patients with Psoriasis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saliva sampling</intervention_name>
    <description>Saliva samples for miRNAs detection will be taken before starting the visit.</description>
    <arm_group_label>Patients with Psoriasis</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva sample for miRNAs extraction (miRNAs 146a, 155, 223, 21)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients affected by Plaque Psoriasis and meeting the inclusion criteria will be&#xD;
        screened for the inclusion in the present study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 70 years old&#xD;
&#xD;
          -  Diagnosis of plaque psoriasis&#xD;
&#xD;
          -  Ability and willingness to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability of unwillingness to give informed consent&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicola Discepoli, DDS, MsC, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Siena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicola Discepoli, DDS, MsC, PhD</last_name>
    <phone>0577 585772</phone>
    <email>nicola.discepoli2@unisi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>AOUS</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Discepoli</last_name>
      <email>ndiscepoli@me.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 19, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2021</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Siena</investigator_affiliation>
    <investigator_full_name>Nicola Discepoli</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Periodontal Diseases</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

